Ras pathways as markers of protection against HIV and methods to improve vaccine efficacy

US10398772B2 · kind B2 · utility

Assignees

• The United States of America, as represented by the Secretary, Department of Health and Human Services · US
• Oregon Health & Science University · US

Inventors

• Genoveffa Franchini · Washington, US
• Rafick-Pierre Sekaly · Montréal, CA
• Slim Fourati · Cleveland, US
• Mark Cameron · Mississauga, CA
• Monica Vaccari · Washington, US
• Luca Schifanella · Bethesda, US
• Shari Gordon · Morrisville, US
• Melvin Doster · Beltsville, US
• Namal Malimbada Liyanage · Rockville, US

Key dates

• Filing date: Jan 8, 2015
• Grant date: Sep 3, 2019
• Expiry date: Jan 8, 2035

Classification

• Technology area (CPC G): Physics
• CPC primary: G01N2800/52
• WIPO field: Pharmaceuticals
• WIPO sector: Chemistry

Abstract

Compositions including a therapeutically effective amount of an HIV immunogen in combination with an agent that stimulates the Ras pathway, wherein the agent is not an aluminum salt, are disclosed. Methods are also disclosed for inducing an immune response to HIV, and/or to inhibit or treat HIV infection, in a subject, using an HIV immunogen and an agent that stimulates the Ras pathway. Methods also are disclosed for determining if an immunogenic composition will induce a protective response, and/or to determine if an immunogenic composition is of use to prevent or treat an HIV infection. The methods including determining if the immunogenic composition increases the level of one or more components of the Ras signaling pathway.